Ian W Flinn

Ian W Flinn, MD, Ph.D. is an internationally recognized clinical investigator whose research focuses on the development of new therapies for patients with lymphoma and CLL. This research includes first-in-human to Phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B-cell receptor pathway, and BCL-2 inhibitors amongst others. He is an author of approximately 200 articles in journals, such as the New England Journal of Medicine, Lancet, Journal of Clinical Oncology, and Blood. Dr. Flinn joined Tennessee Oncology and the Sarah Cannon Research Institute in 2006 and serves as Director of Lymphoma Research. In his role, he oversees lymphoma research throughout Sarah Cannon and its affiliates. Dr. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center.

Dr. Flinn received his bachelor’s degree in economics from Georgetown University in Washington, DC, and graduated from Johns Hopkins University School of Medicine in Baltimore. He then completed his internship and residency at the University of Michigan Medical Center in Ann Arbor. He earned a fellowship in oncology and hematology and a Ph.D. in clinical investigations from Johns Hopkins University School of Medicine. He is board-certified in hematology and medical oncology. Additionally, Dr. Flinn is an associate with Tennessee Oncology, PLLC.